Pmv Pharmaceuticals, INC

PMV Pharmaceuticals stockholders elected two Class III directors, approved executive compensation, and ratified Ernst & Young LLP as auditors.

PMV Pharmaceuticals announced first quarter 2026 financial results, highlighting Orphan Drug Designation for rezatapopt and positive clinical trial updates, with a planned NDA submission in Q1 2027.

PMV Pharmaceuticals announced full year 2025 financial results and provided a corporate update, highlighting progress in its PYNNACLE trial and an anticipated NDA submission for rezatapopt.

PMV Pharmaceuticals announced its third quarter 2025 financial results and positive clinical data for rezatapopt, planning an NDA submission for ovarian cancer in Q1 2027.

PMV Pharmaceuticals announced promising interim Phase 2 data for its monotherapy rezatapopt in solid tumors with a TP53 Y220C mutation, planning an NDA submission for platinum-resistant/refractory ovarian cancer by Q1 2027.

PMV Pharmaceuticals reported its second quarter 2025 financial results, highlighting a cash runway into late 2026 and upcoming interim data from its Phase 2 PYNNACLE clinical trial.

PMV Pharmaceuticals reports a net loss of $18.0 million for Q1 2026, with operating expenses decreasing but interest income also declining, while maintaining sufficient cash for the next 12 months.

PMV Pharmaceuticals, Inc. reported increased net losses for the nine months ended September 30, 2025, while advancing its lead oncology candidate, rezatapopt, towards a pivotal Phase 2 study completion and future NDA submission.

PMV Pharmaceuticals reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses for its lead oncology candidate, rezatapopt, while projecting liquidity until late 2026.

PMV Pharmaceuticals reports a net loss of $17.4 million for Q1 2025 while progressing its lead drug candidate, rezatapopt, through clinical trials.

PMV Pharmaceuticals reported a net loss of $19.2 million for the third quarter of 2024, while continuing to advance its lead product candidate, PC14586, through clinical trials.

PMV Pharmaceuticals reported a net loss of $1.2 million for the second quarter of 2024, while continuing to advance its lead product candidate, PC14586.

PMV Pharmaceuticals reported promising interim Phase 2 data for its lead oncology candidate, rezatapopt, securing Orphan Drug Designation and planning an FDA submission in Q1 2027, despite ongoing significant net losses.

PMV Pharmaceuticals continues to focus on its lead drug candidate, rezatapopt, while managing costs through a restructuring plan.

PMV Pharmaceuticals updates its executive compensation and severance policies, outlining benefits for officers upon termination under various circumstances.

Director Laurie Stelzer was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity compensation plan.

Director Arnold J. Levine was granted 42,000 stock options in PMV Pharmaceuticals, Inc. on June 4, 2026.

Director Carol Giltner Gallagher received a stock option grant and subsequently transferred the holdings to a revocable trust.

Director Kirsten Flowers was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity incentive.

Director Charles M. Baum was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of a standard equity incentive.

PMV Pharmaceuticals President and CEO, David Henry Mack, exercised options to acquire 220,643 shares of common stock at $1.37 per share.

PMV Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.

PMV Pharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

PMV Pharmaceuticals will hold its 2025 annual meeting of stockholders virtually on June 5, 2025, to vote on director elections, executive compensation, and the ratification of the company's independent accounting firm.

PMV Pharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

PMV Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

OrbiMed Advisors and OrbiMed Capital GP V LLC have ceased to be beneficial owners of more than 5% of PMV Pharmaceuticals, Inc. common stock after significant share sales.

OrbiMed Advisors and OrbiMed Capital GP V have reduced their beneficial ownership in PMV Pharmaceuticals, Inc. to 9.4% through recent share sales.

Sio Capital Management, LLC has reported a beneficial ownership of 4.94% in PMV Pharmaceuticals, Inc. as of June 30, 2026.

ArrowMark Colorado Holdings, LLC has reported beneficial ownership of 1,959,579 shares, representing 3.67% of the outstanding common stock of PMV Pharmaceuticals, Inc., as of June 30, 2026.

Euclidean Capital and affiliated entities report a 4.9% beneficial ownership stake in PMV Pharmaceuticals, Inc.

Sio Capital Management, LLC has reported a beneficial ownership of 5.77% in PMV Pharmaceuticals, Inc. as of March 31, 2026.

BML Investment Partners, L.P. has reported a 9.9% beneficial ownership stake in PMV Pharmaceuticals, Inc., holding 5,292,000 shares of common stock.

Sio Capital Management, LLC has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.98% in PMV Pharmaceuticals, Inc. as of September 30, 2025.